



# Standard Medical & Pharmaceuticals Limited

G-8, Amrutha Ville, Opp. Yashodha Hospital, Rajbhavan Road,  
Somajiguda, Hyderabad - 500 082.

14<sup>th</sup> February, 2018

Dept. of Corporate Services  
**The Bombay Stock Exchange Ltd.**  
1<sup>st</sup> Floor, Phiroze Jeejeeboy Towers  
Dalal Street, **MUMBAI - 400001**

Dear Sirs,

**Sub:** Outcome of the 185<sup>th</sup> Meeting of the Board of Directors of the Company and Disclosure under Regulations 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regarding.

**Unit:** Standard Medical & Pharmaceuticals Limited – Scrip Code : 511042

We would like to inform you that the Board of Directors at its meeting held on 14.02.2018, has inter-alia transacted the following business:

1. Considered and approved the unaudited financial results of the company for the Quarter and nine months period ended December 31, 2017 as recommended by the Audit Committee and taken on record together with the Limited Review Report of the Statutory Auditors for the quarter ended on that date.

We are herewith enclosing the Unaudited Financial Results for the Quarter and nine months period ended December 31, 2017 along with the Limited Review Report thereon.

The Board meeting commenced at **3.30 PM** and concluded at **04.10 PM**

This is for your kind information and records.

Thanking You,

Yours faithfully,  
for **Standard Medical & Pharmaceuticals Limited**

  
**Srinivasa Raju Godavarthi**  
Managing Director  
DIN : 01677606

Regd.office: Flat No. B1-35, Mayuri Apartments, Mayuri Marg, Begumpet, Hyderabad – 500016

Phone : 040-2339 4848, 2341 8836, E-mail: [smplhohyd@gmail.com](mailto:smplhohyd@gmail.com), website: [www.smplindia.co.in](http://www.smplindia.co.in)

CIN No.: L24239AP1983PLC004152



**LIMITED REVIEW REPORT**

To,  
**The Board of Directors,**  
**Standard Medical & Pharmaceuticals Limited**

We have reviewed the accompanying statement of Un-audited Financial Results of **STANDARD MEDICAL & PHARMACEUTICALS LIMITED** for the quarter ended **31<sup>st</sup> December, 2017** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI ( Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ( "Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place:** Hyderabad  
**Date:** 14<sup>th</sup> February, 2018

For CHANAMOLU & CO.,  
Chartered Accountants

G. Murali  
Partner

Membership No. 234871





# Standard Medical & Pharmaceuticals Limited

G-8, Amrutha Ville, Opp. Yashodha Hospital, Rajbhavan Road,  
Somajiguda, Hyderabad - 500 082.

## STANDARD MEDICAL & PHARMACEUTICALS LIMITED

Regd. Office Flat No. B1-35, Mayuri Apartments, Mayuri Marg, Begumpet, Hyderabad-500016 - CIN: L24239AP1983PLC004152

### Statement of Standalone Unaudited Financial Results for the Quarter Ended December 31, 2017 (Rs. In Lakhs)

	Particulars	Quarter ended	Quarter ended	Quarter ended	Nine Months	Nine Months	Year Ended
		31.12.2017	30.09.2017	31.12.2016	Period ended 31.12.2017	Period ended 31.12.2016	31.03.2017
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue From Operations	-	-	-	-	-	-
II	Other Income	-	-	-	-	-	3.45
III	Total Income (I+II)	-	-	-	-	-	3.45
IV	EXPENSES	-	-	-	-	-	-
	Cost of materials consumed	-	-	-	-	-	-
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	-	-	-	-	-	-
	Employee benefits expense	-	-	-	-	-	-
	Finance costs	-	-	-	-	-	-
	Depreciation and amortization expense	-	-	-	-	-	-
	Other expenses	0.28	1.19	0.44	1.70	1.33	3.57
	Total expenses (IV)	0.28	1.19	0.44	1.70	1.33	3.57
V	Profit/(loss) before exceptional items and tax (III-IV)	-0.28	-1.19	-0.44	-1.70	-1.33	-0.12
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) before Extraordinary Items and tax (V-VI)	-0.28	-1.19	-0.44	-1.70	-1.33	-0.12
VIII	Extraordinary Items	-	-	-	-	-	-
IX	Profit/(loss) before tax (VII-VIII)	-0.28	-1.19	-0.44	-1.70	-1.33	-0.12
X	Tax expense:	-	-	-	-	-	-
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	-0.28	-1.09	-0.44	-1.70	-1.33	-0.12
XII	Profit/(loss) from discontinued operations	-	-	-	-	-	-
XIII	Tax expense of discontinued operations	-	-	-	-	-	-
XIV	Profit/(loss) from Discontinued operations (after tax) (XII-XIII)	-	-	-	-	-	-
XV	Profit/(loss) for the period (XI+XIV)	-0.28	-1.09	-0.44	-1.70	-1.33	-0.12
XVI	Other Comprehensive Income	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-0.28	-1.09	-0.44	-1.70	-1.33	-0.12
XVIII	Paid-up Equity Share Capital (Face Value of Rs. 10/- per share)	1,084.57	1,084.57	1,084.57	1,084.57	1,084.57	1,084.57
XVII	Earnings per equity share	-	-	-	-	-	-
I	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-

#### Notes to Standalone Financial Results for the Quarter ended December 31, 2017:

- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.02.2018.
- Segment reporting is not applicable as there are no reportable segments.
- Figures for the Previous period have been regrouped or rearranged wherever necessary.
- The Reconciliation of net profit for the quarter and Nine months period ended December 31, 2016 as per IND-AS and as per previous Indian GAAP is as under:

Particulars	for the Quarter ended December 31, 2016 (Rs. In Lakhs)	for the Nine Months Period ended December 31, 2016 (Rs. In Lakhs)
Net Profit/(loss) after Tax as per Previous Indian GAAP	-0.44	-1.33
Net Profit/(loss) after Tax as per IND-AS	-0.44	-1.33

For Standard Medical & Pharmaceuticals Ltd.

Station: HYDERABAD  
Date : 14.02.2018

  
Srinivasa Raju Godavarthi  
Managing Director  
DIN : 01677606

Phone : 040-2339 4848, 2341 8836, E-mail: smplhohyd@gmail.com, website: www.smplindia.co.in

CIN No.: L24239AP1983PLC004152